Visiongain Publishes Therapeutic Respiratory Devices Market Forecast 2020-2030

25 July 2020
Pharma

Visiongain has launched a new report Therapeutic Respiratory Devices Market Forecast 2020-2030: Forecasts and Analysis by Product Type, by Technology, by Filters and Geography, with Profiles of Leading Companies.

According to the report published by Visiongain, the Therapeutic Respiratory Devices market is estimated to be valued at approximately USD xx billion in 2019 and is expected to generate around USD xx billion by 2030, at a CAGR of around xx% between 2020 and 2030. The increasing prevalence of breathing diseases, including chronic obstructive lung disease and sleep apnea, is expected to lead to market growth. WHO estimates that 65 million people are affected by moderate to severe COPD. In addition, the world's third leading cause of death is predicted to be COPD, as estimated by the WHO. The growing need for emergency treatments for prolonged diseases and prolonged lung disease treatment in children and adults is expected to boost market growth.

Therapeutic Respiratory Devices Market is witnessing Growth due to factors such as
Physicians and patients prefer respiratory therapeutic appliances for the treatment of respiratory conditions, since these appliances offer both acute and chronic medical interventions. In the United States, about 12.7 million adults over 18 years reported having COPD, according to the Center for Disease Control and Prevention (CDC). WHO estimates also indicate that possible fatal respiratory conditions, such as tuberculosis, COPD and lung cancer, will be responsible.

Another key growth driver in this market is the increase in the prevalence of sleep apnea. In 2012, approximately forty million Americans were affected by chronic sleep disorder, according to statistics published by the National Sleep Foundation. The prevalence of obstructive sleep apnea in the U.S., with a diagnosis ratio of about 1 million per 22, was also calculated at 12 million. Due to increasing prevalence of cardiovascular diseases, high blood pressure, obesity, etc., the prevalence of this disease is expected to continue to increase during the forecast period. The market growth is expected to be driven by these factors.

Factors Affecting Jet Nebulizer Performance and Drug Delivery
Aerosol therapy has many factors to keep in mind for respiratory therapists. Nebuliser layout is a key determinant of the particle size and production efficiency that, in line with the factors mentioned below, ensures the ultimate quality of medication. There are several forms of nebulizers on the market and various studies have shown that there is a difference in performance between suppliers and even the same producing nebulizers.

Gas Flow and Pressure
Jet nebulizers are designed to operate with varying levels of pressure and compressed gas streaming. Every jet nebulizer model is designed for the best possible operation at a certain flow of 2–8 L / min that should be indicated on the label. When a jet nebulizer is operated with lower flow or pressure, the particle size increases. For example, when driven by a compressor producing 13 psi, a jet nebulizer designed to work 6–8 L / min at 50psi produced greater particles. Thus, a compressor or gas supply that correlates to the planned designs of jet nebulizers should be matted. The stream of gas is also reversed in process of nebulization. Using a higher gas flow rate in aerosol therapy will decrease the amount of treatment time needed to deliver the set amount of drug.

Fill and Dead Volumes
Another factor which affects the efficiency of jet nebulizers is changing the fill volume. Studies show that nebulizers have increased efficiency due to a fixed dead volume, thereby reducing the proportion of death within the nebulizer by an increase in fill volume. While efficiency increases with a greater filling volume, the nebulization time also increases.

Gas Density
The gas density used to run a jet nebulizer can have a similar offsetting effect on aerosol deposition through the impact of aerosol output and particulate size. The aerosol supply with helium-oxygen mixtures (heliox) for instance can improve the lung deposition by up to 50%. Using heliox at the same flow rate as the air or oxygen, particle size and aerosol output are reduced and treatment times are increased. The heliox flow should therefore be increased 1,5-2 times to restore the size and output of the particle to air or oxygen levels.

Breathing Pattern
Breathing pattern influences aerosol deposition in the lower respiratory tract. The patient should be instructed to do tidal breathing with periodic deep breaths during aerosol therapy.

Device Interface
Medical aerosols can be used with a mask or a mouthpiece. Ideally, you should use a mouthpiece. The nose uses more aerosol than the mouth to filter, therefore it is advisable to use a mouthpiece. Mouthpieces for children and little children can not be used. Moreover, it may be uncomfortable to use a mouthpiece for long aerosol treatment. The use of a mask raises the quantity of aerosol put on the head, eyes and nose. It is essential that the person is advised to inhale through the mouth during an aerosol treatment, whether a mouthpiece or a face mask are used. Proper mask fit and design can optimize the inhaled dose and reduce deposition to the eyes. The respiratory therapist must keep all of these factors in mind when practicing or equipping patients.

Factors Affecting pMDI Performance and Drug Delivery
Many pMDIs are meant to provide an actuation medication dosage of 100 μm. Like other aerosol generators, the pMDI medication supplies amount to about 10-20% of the nominal dose per actuation. The aerosol particle size produced by the pMDI fine particle fraction is less than 5μm in aerodynamic diameter. Several factors affect the performance of pMDI and the delivery of aerosols. Comprehension of the impacts of these factors will improve the effectiveness of pMDIs in patients with pulmonary diseases.

Spacers
The application of an inhaled dose and clinical effect of pMDI with pMDI should at least be equivalent to the correct use of pMDI. A spacer offers extra density that reduces the aerosol velocity of a pMDI to rising particle size. The persistence of aerosol or dosage of release is based on the spacer's size and shape and the electrostatic effect on plastic spacer inner walls. Spacers minimize oral deposition but provide only limited protection against poor control of hand respiration. When using a spacer, it is important that the inhalation of the patient is coordinated slightly before the inhaler is activated. Many ranges need to detach the inhaler from the actuator of the distributor and insert it into a specific gap on the distance. It is important to understand that the dosage distribution in certain spacer models can be compromised if the system does not properly match the pMDI or if a specific orifice or actuator in the spacer is used. Clinicians or physicians sometimes create makeshift storage chambers with plastic containers (for instance, water bottles) or of other equipment (for example, toilet rolls of paper). This can work as a spacer and protect against lower dose with pMDI action before inhalation, but does not protect from exhalation. Also, their performance is variable, so they should not be considered as suitable replacements for a commercially available spacer.

Dry-powder inhalers are mobile, flow-driven, inspiratory inhalers administering dry pulp formulations. Inhalers are inspiratory inhalers. DPIs are propellant-free and breathable. The inspiratory work of the patient, both the inhaled volume and its inspiratory flow rate, generates the energy to break down small medicinal particles and disperses particles as aerosol emanating from the device. DPIs shall coordinate inhalation release of the drug. They were designed to overcome problems with the use of metered-dose inhalers. They are often prescribed to make the patient overall more user-friendly and predictable.

Increasing Sleep Apnea Obstructive Incidence Is One Of The Growth Factors
It was estimated that positive airways will dominate the market in 2016, accounting for over 52 percent of the revenue share, with the fastest growth expected over the forecast period. The growth of this segment can be attributed to increasing sleep apnea obstructive incidence. This is due to lifestyle-related conditions such as obesity, alcohol use, smoking, and craniofacial malnormalities. In the United States at least 25 million people are reported to have obstructive sleep apnea by the 2014 National Healthy Sleep Awareness Project. Increasing use of these devices by the geriatric patient base is also responsible for the growth of therapeutic respiratory devices market.

Among the factors that drive the market for HEPA filter technology is the occurrence and propagation of respiratory diseases
With around 37 percent of the revenue share, HEPA filter software dominated the market in 2014. Particle Air (HEPA) high efficiency filters are used on various therapeutic respiratory devices for the removal and retention of particulate matter. According to CDC recommendations, HEPA air filtration systems are needed for therapeutic tools. As in the United States. State Department of Energy, 99.97% of particles larger than 0.3 microns disable HEPA filters. In the next seven years, technological progress in the segment is expected to have a positive market impact. This includes washable HEPA filters and HEPA 4 technology, which is ranked by the filter at the minimum efficiency reporting value (MERV). It is used to assess the air filter's ability to remove particles from the air.

Shift in Trends

Regional Market Analysis
Due to the large geriatric population base and the increased prevalence of chronic respiratory diseases, North America dominated the market in 2016. In addition, North American markets play a major part due to reimbursement available on the accounts of US healthcare centres, improved healthcare awareness, improved infrastructure, increased outpatient operations and economic growth favored by increased insurance cover. The health plans of government including Medicaid and Medicare with the help of CMS also fuel the development of the demand for therapeutic respiratory equipment in this area. These health plans cover the respiratory therapy using respiratory devices such as Continuous Positive Airway Pressure devices for treatment of COPD and Obstructive Sleep Apnea (OSA).

Due to the factors such as increasing prevalence of asthma in adults as well as in children and technical developments asia pacific is expected to grow most rapidly during the forecast period. According to statistics published by the Global Asthma Initiative (GINA), by 2025 an additional 100 million people with asthma are expected to be increased. In contrast, the growing need for domestic health care facilities in this region also has a high impact. In fact, the significant growth levels in this area over the forecast period are responsible for increasing disposable income and lifestyle-related changes.

Top Companies
Koninklijke Philips NV
Medtronic PLC
ResMed Inc
CareFusion Corporation
GE Healthcare
Becton, Dickinson and Company
Hamilton Medical
Hill-Rom Services Inc.
Airsep Corporation
Philips Healthcare
Compumedics Ltd.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

Read

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

Read

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

Read

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever